Zealand Pharma A/S

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

In March 2022, Adam Steensberg became CEO of struggling Zealand Pharma and almost three years later to the day, the firm’s future looks far brighter with a promising pipeline and a multibillion dolla

Roche has made a major advance in its bid to join Novo Nordisk and Eli Lilly at the top of the obesity tree by paying a whopping $1.65bn upfront fee to co-develop and co-commercialize Zealand’s closel

Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab